Skip to main content

Phase 3 vs Approved — Neurology Deal Valuation Comparison

Phase 3 Median Upfront
$770M
Total: $4.1B
Approved Median Upfront
$2.2B
Total: $7.1B
Stage Premium
75%
Approved premium over Phase 3
Phase 3 Royalties
16.1%-24.7%
vs Approved: 19.8%-30%
Model Your Deal

Market Analysis

The Phase 3 to Approved transition in neurology represents a significant value inflection point. Approved deals carry a median total deal value of $7.1B compared to $4.1B at Phase 3, a 75% premium reflecting clinical de-risking. Upfront payments increase from $770M to $2.2B.

Deal structures shift as assets advance. Phase 3 deals allocate 19% to upfront and 81% to milestones, while Approved deals shift to 31%/69%. Development milestones move from $492M to $244M, and royalty rates evolve from 16.1%-24.7% to 19.8%-30%.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Phase 3 to Approved in neurology?
Approved neurology deals command a 75% premium over Phase 3 in total deal value ($7.1B vs $4.1B). Upfronts increase from $770M to $2.2B, reflecting the de-risking value of clinical progression.
How do deal structures differ between Phase 3 and Approved in neurology?
Phase 3 deals are more milestone-weighted (81% milestones), reflecting higher clinical risk. Approved deals shift toward higher upfront allocations (31% upfront) as clinical de-risking reduces the need for contingent milestone structures.
When is the optimal time to license a neurology asset?
The optimal licensing window depends on strategic priorities. Phase 3 assets offer lower entry cost for licensees, while Approved assets provide more certainty. The 75% premium from Phase 3 to Approved reflects the value created by clinical data, making the transition point critical for deal timing.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Phase 3 Neurology Deals

View

Approved Neurology Deals

View

Phase 2 Deal Benchmarks

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included